Article Text

Download PDFPDF

Denosumab, cortical bone and bone erosions in rheumatoid arthritis
  1. Maurizio Rossini,
  2. Giovanni Adami,
  3. Ombretta Viapiana,
  4. Luca Idolazzi,
  5. Davide Gatti
  1. Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy
  1. Correspondence to Professor Maurizio Rossini, Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, Verona 37134, Italy; maurizio.rossini{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Takeuchi et al1 demonstrate an additional inhibitory effect on the progression of bone erosions in rheumatoid arthritis (RA) with the addition to methotrexate of an anti-receptor activator of nuclear factor kappa-B ligand (RANKL) antibody, denosumab, confirming results already reported 8 years ago by Cohen and colleagues.2 Insufficient inhibition of structural joint damage by disease-modifying antirheumatic drugs (DMARDs) was reported despite clinical improvement,3–5 and recently two meta-analysis6 , …

View Full Text

Linked Articles